Podcast 23 Aug 2024New German biotech spins out to develop radiotherapeutics While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company August 23, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 22 Aug 2024 Seven companies transforming the biotech industry in Italy Delve into Italy’s biotech landscape with seven companies that are leading the charge in the European country. August 22, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2024 CureVac: From a failed drug to a €1.45 billion deal In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around. August 1, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2024 Influenza solution deals pile up as pandemic preparedness increases Influenza deals have been piling up in the last few weeks. Discover why that is and how are companies and government preparing for pandemics. July 29, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 26 Jul 2024 Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies Discover the field of agonistic GPCR antibodies after Confo therapeutics successfully raised $60 million in its series B round. July 26, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 23 Jul 2024 First AKT-targeting drug capivasertib to hit the market, could it open the door for more? As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out! July 23, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 17 Jul 2024 Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it Discover yet another exciting deal in biotech with Asceneuron raising $100 million to advance its Alzheimer’s candidate, ASN51. July 17, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2024 German biotech raises $150M on its way to tackle cancer therapy resistance On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round. July 16, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Jul 2024 Five universities in Canada to build a career in biotech in 2024 Delve into Canada’s biotech education ecosystem with five universities putting industry experience forward. July 12, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 11 Jul 2024 CDMO trends post-Wuxi’s exit from the US: who will take its place? The BIOSECURE Act is reshuffling the deck and Indian CDMOs are looking good. Discover the trends in this evolving landscape. July 11, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Expert Advice 5 Jul 2024 The ABC of biotech startup funding Funding a biotech startup can be challenging. Delve into our guide to navigate this complicated investment landscape. July 5, 2024 - 21 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 28 Jun 2024Priovant – finding treatments for autoimmune diseases Listen to our conversation with Priovant Therapeutics, developing therapies for autoimmune diseases with high morbidity. June 28, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More